CN102793801A - Tibetan medicine for treating angina pectoris - Google Patents
Tibetan medicine for treating angina pectoris Download PDFInfo
- Publication number
- CN102793801A CN102793801A CN2012103289781A CN201210328978A CN102793801A CN 102793801 A CN102793801 A CN 102793801A CN 2012103289781 A CN2012103289781 A CN 2012103289781A CN 201210328978 A CN201210328978 A CN 201210328978A CN 102793801 A CN102793801 A CN 102793801A
- Authority
- CN
- China
- Prior art keywords
- tibetan medicine
- angina pectoris
- medicine
- blood
- tibetan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 61
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 31
- 239000009609 fructus phyllanthi Substances 0.000 claims description 13
- 210000000582 semen Anatomy 0.000 claims description 13
- 240000004460 Tanacetum coccineum Species 0.000 claims description 12
- ROVGZAWFACYCSP-MQBLHHJJSA-N [2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OC1C(C)=C(C\C=C/C=C)C(=O)C1 ROVGZAWFACYCSP-MQBLHHJJSA-N 0.000 claims description 12
- 229940015367 pyrethrum Drugs 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 208000029078 coronary artery disease Diseases 0.000 abstract description 7
- 208000002193 Pain Diseases 0.000 abstract description 6
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 230000036407 pain Effects 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 5
- 239000002671 adjuvant Substances 0.000 abstract description 4
- 235000013399 edible fruits Nutrition 0.000 abstract description 3
- 241001139841 Chrysanthemum tatsienense Species 0.000 abstract description 2
- 244000119298 Emblica officinalis Species 0.000 abstract description 2
- 235000015489 Emblica officinalis Nutrition 0.000 abstract description 2
- 244000270834 Myristica fragrans Species 0.000 abstract description 2
- 235000009421 Myristica fragrans Nutrition 0.000 abstract description 2
- 240000000513 Santalum album Species 0.000 abstract description 2
- 235000008632 Santalum album Nutrition 0.000 abstract description 2
- 208000019622 heart disease Diseases 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 3
- 241000871539 Choerospondias Species 0.000 abstract 1
- 235000018912 Chrysanthemum tatsienense Nutrition 0.000 abstract 1
- 239000001702 nutmeg Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 24
- 238000011282 treatment Methods 0.000 description 17
- 238000002156 mixing Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 108010088842 Fibrinolysin Proteins 0.000 description 6
- 229940012957 plasmin Drugs 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 206010003119 arrhythmia Diseases 0.000 description 4
- 230000006793 arrhythmia Effects 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- -1 dry below 60 °C Substances 0.000 description 3
- 229960003699 evans blue Drugs 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 230000003533 narcotic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241001533085 Aquilaria sinensis Species 0.000 description 1
- 206010003175 Arterial spasm Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000131317 Capitulum Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001081833 Myristicaceae Species 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000221035 Santalaceae Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 244000218979 Spondias axillaris Species 0.000 description 1
- 235000014116 Spondias axillaris Nutrition 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 208000010540 rapid respiration Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a Tibetan medicine for treating angina pectoris. The Tibetan medicine comprises active ingredients or comprises active ingredients and pharmaceutically acceptable adjuvants, wherein the active ingredients are prepared from agilawood, axillary choerospondias fruit, nutmeg, sandalwood, phyllanthus emblica and pyrethrum tatsienense according to certain weight ratio. The Tibetan medicine can be prepared into any commonly used oral preparation form. The Tibetan medicine has the functions of promoting qi to activate blood, removing stasis to stop pain, increasing the coronary blood-flow volume and relieving angina pectoris. The Tibetan medicine is used for treating sudden heart diseases caused by dragon according to the Tibetan medicine science and is particularly used for treating coronary heart disease and angina pectoris according to the traditional Chinese medicine science.
Description
Technical field
The present invention relates to a kind of Tibetan medicine of treating angina pectoris.
Background technology
Coronary heart disease is a kind of common cardiovascular disease, is the modal cause of death in developed country's population in the world, also is the underlying cause of death that China's recent two decades comes population.Angina pectoris is a Clinical types the most common in the patients with coronary heart disease, to its control and further investigation, is the emphasis of medical domain always.Angina pectoris is common clinical, frequently-occurring disease.In recent years, sickness rate is in rising trend, has brought grave danger for people's health.Therefore, the control angina pectoris has become one of important topic of medical circles.
Modern medicine thinks that angina pectoris is on the basis of coronary atherosclerosis, and arteriospasm or pathological changes intra-arterial thrombosis take place, and makes tremulous pulse take place serious narrow or obstruction, causes acute ischemia to be fallen ill.Doctor trained in Western medicine is numerous to the Therapeutic Method of angina pectoris, but should disease often be prone to recurrence, and it is often not satisfactory to correct ischaemic ECG change.Angina pectoris belongs to traditional Chinese medical science thoracic obstruction category, and its pathogenic characteristic is a simulataneous insufficiency and excessive, deficiency in origin and excess in superficiality.
Though the treatment treating coronary heart disease and angina pectoris is a lot of at present, curative effect still can not be satisfactory.Therefore, there is tight demand in people's Tibetan medicinal preparation that curative effect is better treated angina pectoris.
Up to now, also do not find the report of any relevant Tibetan medicine compositions of the present invention.The inventor is through research repeatedly, and the repeated validation through animal and clinical trial, found the Tibetan medicine oral drugs that the treatment of better curative effect angina pectoris is arranged finally, thereby accomplished the present invention.
Summary of the invention
The object of the invention just provides a kind of Tibetan medicine of more effectively treating angina pectoris.
Medicine of the present invention is a kind of Tibetan medicine; Formed or be made up of active component and acceptable accessories by active component, wherein said active component is to be processed by following bulk drugs: Lignum Aquilariae Resinatum, Fructus Choerospondiatis, Semen Myristicae, Lignum Santali Albi, Fructus Phyllanthi, west szechwan pyrethrum.
It has selected Lignum Aquilariae Resinatum, Fructus Choerospondiatis, Semen Myristicae, Lignum Santali Albi, Fructus Phyllanthi, west szechwan pyrethrum to make up as raw material, and wherein (1) Lignum Aquilariae Resinatum is the timber that thymelaeceae plant Lignum Aquilariae Resinatum Aquilariasinensis (Lour.) Gilg contains resin.Nature and flavor are hot, bitter, tepor; Return spleen, stomach, kidney channel.Have promoting the circulation of QI to relieve pain, warming middle-JIAO to arrest vomiting, the function of helping inspiration to relieve asthma.Be used for the vexed pain of breast abdominal distention, gastrofrigid vomiting singultus, the QI rising in reverse order of suffering from a deficiency of the kidney dyspnea with rapid respiration.Have pharmacological actions such as inhibition, antibiotic, pain relieving, calmness, Zhichuan, blood pressure lowering, arrhythmia and resisting myocardial ischemia.(2) Fructus Choerospondiatis is the dry mature fruit of Anacardiaceae plant Fructus Choerospondiatis Choerospondias axillaris (Roxb.) Burtt et Hill.Nature and flavor are sweet, sour, and are flat.Have promoting flow of QI and blood, nourish heart, the effect of calming the nerves.Be used for qi depression to blood stasis, the thoracic obstruction is had a pain, shortness of breath and palpitation, irritability.Fructus Choerospondiatis total flavones (TFC) has the expansion effect of guarantor and antiarrhythmic effect to animal anoxia enduring and acute myocardial ischemia, and platelet aggregation is had the obvious suppression effect, can make the blood flow pick up speed, improves blood circulation and microcirculation.(3) Semen Myristicae is the dry kernel of myristicaceae plant Semen Myristicae Myristica fragrans Houtt..Nature and flavor are hot, temperature; Return spleen, stomach, large intestine channel.Has warming middle-JIAO to promote flow of QI, the function of relieving diarrhea with astringents.Be used for Deficiency and coldness of spleen and stomach, incessant chronic diarrhea, abdominal distention, lack of appetite vomiting.Effect and antibacterial action with significant anesthesia performance, enhancing tryptamines.(4) Lignum Santali Albi is the heartwood of Santalaceae Lignum Santali Albi platymiscium Lignum Santali Albi Santalum album L. trunk.Nature and flavor are hot, temperature; Return spleen, stomach, the heart, lung meridian.Has the circulation of qi promoting warming middle-JIAO, the effect of appetizing pain relieving.Be used for QI stagnated by cold, chest pain, stomachache, stomachache lack of appetite; Coronary heart disease, angina pectoris.Have the enhance gastrointestinal wriggling, the secretion of facilitating digestion liquid, diuresis is to the pharmacological actions such as inhibition of dysentery bacterium, tubercule bacillus.(5) Fructus Phyllanthi is the fruit of Euphorbiaceae phyllanthus plant Fructus Phyllanthi Phyllanthus emblica L..Sweet in the mouth, acid, puckery, cool in nature; Has clearing away heat and cooling blood, promoting digestion and invigorating the stomach, the effect of promoting the production of body fluid to quench thirst; Cure mainly the heat in blood blood stasis, dyspepsia, abdominal distention, cough, laryngalgia, xerostomia and vitamin C deficiency disease; In Tibetan medicine, cure mainly Baconic's disease, red crust disease, disorders of blood, hypertension etc.; In recent years result of study shows, has antiinflammatory, antioxidation, and defying age such as protects the liver at effect.(6) west szechwan pyrethrum is the dry capitulum of Compositae Chrysanthemum plant Pyrethrum tatsienense (Bur. et Franch.) Ling ex Shih.Cold in nature, bitter in the mouth.Have invigorate blood circulation, the effect of damp eliminating, anti-inflammatory analgetic.Cure mainly traumatic injury, damp and hot.
Make each efficacy of drugs produce synergism these drug regimens, thereby can effectively treat angina pectoris.
The consumption of Tibetan medicine component of the present invention is also groped to sum up to draw through the inventor in a large number, and each crude drug consumption is for all to have better curative effect in the following weight parts scope:
Lignum Aquilariae Resinatum 250～750g, Fructus Choerospondiatis 250～750g, Semen Myristicae 250～750g, Lignum Santali Albi 250～750g, Fructus Phyllanthi 275～775g, west szechwan pyrethrum 400～1200g.
Be preferably: Lignum Aquilariae Resinatum 500g, Fructus Choerospondiatis 500g, Semen Myristicae 500g, Lignum Santali Albi 500g, Fructus Phyllanthi 550g, west szechwan pyrethrum 800g.
The preparation of Tibetan medicine active component of the present invention can be the crude drug convection drying of above-mentioned consumption to be pulverized process; Also can adopt conventional method such as the decoction and alcohol sedimentation technique of Chinese medicine preparation or ethanol extract from water precipitation (referring to Cao Chunlin chief editor's " pharmaceutics of Chinese drugs " the 73rd～74 page, Science and Technology of Shanghai publishing house publishes in November, 1986) to make the crude drug of above-mentioned consumption.
The active component of Tibetan medicine of the present invention can add various conventional adjuvant required when preparing different dosage form; Like disintegrating agent, lubricant, binding agent etc. with the method for Chinese medicinal of routine (referring to Cao Chunlin chief editor's " pharmaceutics of Chinese drugs "; Science and Technology of Shanghai publishing house publishes in November, 1986) be prepared into any peroral dosage form commonly used, like powder, pill, capsule, granule, tablet etc.
Tibetan medicine of the present invention has promoting flow of QI and blood, stasis-dispelling and pain-killing, coronary blood flow increasing, the function of allevating angina pectoris.Tibetan medicine: be used for the sudden cardiac disease that causes by " dragon ".The traditional Chinese medical science: be used for coronary heart disease, angina pectoris.
The usage and dosage of Tibetan medicine of the present invention is: oral; A 2g, 1～3 time on the one.
[specific embodiment]
Below come further to set forth Tibetan medicine of the present invention through embodiment method for preparing.
The powder preparation of [embodiment 1] Tibetan medicine of the present invention:
Take by weighing Lignum Aquilariae Resinatum 500g, Fructus Choerospondiatis 500g, Semen Myristicae 500g, Lignum Santali Albi 500g, Fructus Phyllanthi 550g, west szechwan pyrethrum 800g, be ground into fine powder after the mixing jointly, mixing, packing promptly gets powder.
The pill preparation of [embodiment 2] Tibetan medicine of the present invention:
Take by weighing Lignum Aquilariae Resinatum 400g, Fructus Choerospondiatis 550g, Semen Myristicae 550g, Lignum Santali Albi 400g, Fructus Phyllanthi 600g, west szechwan pyrethrum 850g, be ground into fine powder after the mixing jointly, mixing is used water pill, dry below 60 ℃, and polishing, packing promptly gets pill.
The granule preparation of [embodiment 3] Tibetan medicine of the present invention:
Take by weighing Lignum Aquilariae Resinatum 600g, Fructus Choerospondiatis 400g, Semen Myristicae 550g, Lignum Santali Albi 450g, Fructus Phyllanthi 400g, west szechwan pyrethrum 950g, be ground into fine powder after the mixing jointly, mixing adds adjuvant and processes granule, dry below 60 ℃, and granulate, packing promptly gets granule.
The capsule preparation of [embodiment 4] Tibetan medicine of the present invention:
Take by weighing Lignum Aquilariae Resinatum 650g, Fructus Choerospondiatis 400g, Semen Myristicae 550g, Lignum Santali Albi 600g, Fructus Phyllanthi 400g, west szechwan pyrethrum 750g, be ground into fine powder after the mixing jointly, mixing, the gelatine capsule of packing into promptly gets capsule.
The preparation tablets of [embodiment 5] Tibetan medicine of the present invention:
Take by weighing Lignum Aquilariae Resinatum 700g, Fructus Choerospondiatis 300g, Semen Myristicae 400g, Lignum Santali Albi 500g, Fructus Phyllanthi 550g, west szechwan pyrethrum 900g, be ground into fine powder after the mixing jointly, mixing adds adjuvant and processes granule, dry below 60 ℃, and granulate, tabletting promptly gets tablet.
Below come further to set forth the beneficial effect of Tibetan medicine of the present invention, these Test Example to comprise that the pharmacodynamics test of Tibetan medicine embodiment 1 of the present invention and clinical observation on the therapeutic effect test through Test Example.
The pharmacodynamics test of [Test Example 1] Tibetan medicine embodiment 1 of the present invention:
Test material: anthology invention Tibetan medicine embodiment 1; Creatine kinase testing cassete and lactic acid dehydrogenase testing cassete are produced by the big biochemical instrument company limited of China; The Wistar rat is provided by Qinghai Province's Experimental Animal Center.
Experimental technique and result: 1, to the research of plasmin activity: get 40 of normal rats, be divided into 4 groups at random, be respectively matched group (waiting capacity 5% glucose solution) and Tibetan medicine embodiment 1 (0.5g/kg of the present invention by body weight; 1.0g/kg, 2.0g/kg) basic, normal, high dose groups, gastric infusion 20ml/Kg; Continuous 7d, 30min after the last administration, injecting narcotic; Back of the body position is fixing, gets anticoagulation 2ml mixing, high speed centrifugation under the water-bath by ventral aorta behind the 60min.Get 0.5ml blood plasma and add to mixing in the refrigerative 5ml acetic acid solution, leave standstill 30min, then low-speed centrifugal; Get its deposition partial purification; Add BAS 0.5ml, the ultrasound wave dissolving, record is formed up to the consoluet time from grumeleuse; Calculate plasmin activity unit's (u=10000/ dissolution time), the result sees table 1.
The influence of 1 pair of plasmin activity of table 1 Tibetan medicine embodiment of the present invention (x ± s, n=10)
Group dosage (g/kg) plasmin activity (u)
Matched group 5% glucose 80.3 ± 15.8
Low dose group 0.5 90.5 ± 14.8
*
Middle dose groups 1.0 96.6 ± 14.7
*
High dose group 2.0 101.6 ± 15.2
*
Explain: relatively with matched group:
*P<0.05.
2, to the research of cerebral ischemia: get 40 of normal rats, group technology and dosage and administration number of times are with " 1 ".30min after the last administration, injecting narcotic, back of the body position is fixing; Operation separates bilateral common carotid arteries, vena femoralis injection azovan blue 40mg/kg behind the 30min, ligation bilateral carotid arteries immediately; Haircut is got brain and is weighed behind the ligation 2h; Calculate cerebral index (the heavy mg/ body weight of brain g), it is roasting to constant weight that a part of cerebral tissue is put in 110 ℃ of baking ovens constant temperature, calculates brain water content.Other gets the part cerebral tissue and weighs, and grinds to be placed in the formamide solution, and incubation 48h in 45 ℃ of calorstats gets upper strata liquid and measures the OD value in the 620nm place behind the high speed centrifugation, press standard curve and calculate azovan blue content in the brain, and the result sees table 2.
The influence of 1 pair of cerebral ischemia of table 2 Tibetan medicine embodiment of the present invention (x ± s, n=10)
Group dosage (g/kg) azovan blue content (μ g/g) cerebral index (mg/g) brain water content (%)
Matched group 5% glucose 15.3 ± 2.3 6.1 ± 0.7 81.4 ± 2.1
Low dose group 0.5 11.5 ± 1.7
*5.4 ± 0.6
*76.7 ± 1.4
*
Middle dose groups 1.0 10.8 ± 1.8
*5.3 ± 0.7
*76.1 ± 1.5
*
High dose group 2.0 10.2 ± 1.7
*5.1 ± 0.8
*75.3 ± 1.6
*
Explain: relatively with matched group:
*P<0.05.
3, to thrombotic research: get 40 of normal rats, group technology and dosage and administration number of times are with " 1 ".30min after the last administration, injecting narcotic, back of the body position is fixing, separates left side external jugular vein and right carotid.Get one on the cotton thread of 5cm and weigh, make right side arterial cannulation blood flow get into the left side external jugular vein, behind the circulation 15min through the polyethylene tube that is equipped with cotton thread; Carrying out thrombosis by the method for bypass measures; Take out the cotton thread wet weight of thrombus of weighing, calculate the poor of twice weight, the result sees table 3.
1 pair of thrombotic influence of table 3 Tibetan medicine embodiment of the present invention (x ± s, n=10)
Group dosage (g/kg) thrombosis poor (mg)
Model control group 5% glucose 14.5 ± 1.3
Low dose group 0.5 10.9 ± 1.6
*
Middle dose groups 1.0 10.1 ± 1.8
*
High dose group 2.0 9.2 ± 2.3
*
Explain: relatively with matched group:
*P<0.05.
Compare with matched group, Tibetan medicine embodiment 1 of the present invention all has significant difference (P < 0.05) at aspects such as increasing plasmin activity, ischemia resisting, antithrombotic formation.Point out Tibetan medicine embodiment 1 of the present invention that significant increase plasmin activity, ischemia resisting, anti-thrombosis function are arranged, and dosage is high more, effect is remarkable more, but group difference and little.
[Test Example 2] Tibetan medicine embodiment 1 treatment angina pectoris clinical observation on the therapeutic effect of the present invention:
Physical data: 120 routine angina pectoris patients all meet WHO standard and " traditional Chinese medical science disease diagnosis criterion of therapeutical effect ", " new Chinese medicine clinical research guideline " middle angina pectoris diagnostic criteria and syndrome of blood stasis due to qi deficiency diagnostic criteria.Be divided into two groups at random, wherein 60 examples are organized in treatment, male 38 examples, women 22 examples; 42～66 years old age, average 60.8 years old; The course of disease 6 months～11 years, average 8.5 years; Merge arrhythmia person's 2 examples, hyperlipemia person's 11 examples, hyperpietic's 14 examples, glycosuria patient 10 examples.Matched group 60 examples, male 34 examples, women 26 examples; 43～67 years old age, average 60.3 years old; The course of disease 6 months～14 years, average 8.3 years; Merge arrhythmia person's 3 examples, hyperlipemia person's 12 examples, hyperpietic's 12 examples, glycosuria patient 9 examples.Unusual or the T ripple inversion of ST-T all appears in all patient's Electrocardioscopy, and two groups of patients compare at aspects such as sex, age, the courses of disease, the difference not statistically significant (P 0.05), have comparability.
Therapeutic Method: two groups are all adopted conventional therapy, comprise aspirin, nitrate esters, beta-blocker and ACEI class medicine, controlling blood pressure and blood glucose.The treatment group adds Tibetan medicine embodiment 1 of the present invention on this basis, each 2g, and 3 times/d, be 4 weeks two groups of courses of treatment.
Observation index: promoting the circulation of blood before and after all patient treatments, routine urinalysis, liver, renal function, blood glucose, blood fat, myocardium zymetology, blood viscosity are measured, routine electrocardiogram, 24h ambulatory electrocardiogram, cardiac ultrasonic inspection.
Clinical efficacy evaluation criteria: the standard that adopts the revision of combination of Chinese and Western medicine method treatment angina pectoris arrhythmia research informal discussion club; Produce effects: angina pectoris attacks disappears or basic the disappearance after the course of treatment; Or attack times reduces more than >=80%, or the nitroglycerin consumption reduces＞80%; Effectively: angina pectoris has bigger improvement after 1 course of treatment, and the angina pectoris attacks number of times reduces 50%～80%; Invalid: the angina pectoris attacks number of times reduces＜50% after 1 course of treatment, or the nitroglycerine tablets consumption reduces＜50%.The ECG curative effect standard is according to " Chinese common cardiovascular and cerebrovascular disease practice guidelines ".Produce effects: transference cure, resting electrocardiogram inspection mainly lead the ischemic ST recovery normally, or recover greater than 0.1 mV, and negative T wave transfers to uprightly, and the treadmill exercise test transfers feminine gender to by the positive.Effectively: sx, resting electrocardiogram ischemic ST recover more than 0.05 mV or the T ripple that mainly leads becomes more than 50%.Invalid: symptom basic with treatment before identical, the resting electrocardiogram check, the ST section is forced down or the T ripple is inverted and is not had improvement.
Produce effects adds and effectively adds up to total effective rate.
Clinical observation result is seen table 4, table 5.
Table 4 liang group patient clinical symptoms curative effect comparison (example, %)
Group example digital display is imitated the enabledisable total effective rate
Treatment organizes 60 32 (53.3) 25 (41.7) 3 (5.0) 57 (95.0)
*
Matched group 60 18 (30.0) 17 (28.3) 25 (41.7) 35 (58.3)
Explain: relatively with matched group:
*P<0.05.
Table 5 liang group patient ECG curative effect comparison (example, %)
Group example digital display is imitated the enabledisable total effective rate
Treatment organizes 60 21 (35.0) 20 (33.3) 19 (31.7) 41 (68.3)
*
Matched group 60 16 (26.7) 12 (20.0) 32 (53.3) 35 (46.7)
Explain: relatively with matched group:
*P<0.05.
Untoward reaction: all do not see the untoward reaction relevant in two groups of patient treatments, the equal not statistically significants of difference such as hematuria, stool routine examination, hepatic and renal function, blood glucose, blood fat, blood pressure, coagulation indexes before and after the treatment with medicine.
This result of study shows: Tibetan medicine embodiment of the present invention 1 is clinical, and to be used to treat angina pectoris evident in efficacy, can improve the thoracic obstruction, pained, symptom such as breathe hard rapidly, patient's electrocardiogram developed be able to correct, and do not have obvious adverse reaction.Therefore, the clinical efficacy of Tibetan medicine embodiment 1 treatment angina pectoris of the present invention is definite, safe.
Claims (4)
1. Tibetan medicine of treating angina pectoris; It is characterized in that it is made up of active component or is made up of active component and acceptable accessories, wherein said active component is to be processed by following bulk drugs: Lignum Aquilariae Resinatum 250～750g, Fructus Choerospondiatis 250～750g, Semen Myristicae 250～750g, Lignum Santali Albi 250～750g, Fructus Phyllanthi 275～775g, west szechwan pyrethrum 400～1200g.
2. Tibetan medicine according to claim 1, wherein said active component are to be processed by following bulk drugs: Lignum Aquilariae Resinatum 500g, Fructus Choerospondiatis 500g, Semen Myristicae 500g, Lignum Santali Albi 500g, Fructus Phyllanthi 550g, west szechwan pyrethrum 800g.
3. Tibetan medicine according to claim 1 and 2, it is a peroral dosage form.
4. Tibetan medicine according to claim 3, it is powder, pill, granule, capsule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210328978.1A CN102793801B (en) | 2012-09-07 | 2012-09-07 | Tibetan medicine for treating angina pectoris |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210328978.1A CN102793801B (en) | 2012-09-07 | 2012-09-07 | Tibetan medicine for treating angina pectoris |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102793801A true CN102793801A (en) | 2012-11-28 |
| CN102793801B CN102793801B (en) | 2014-02-26 |
Family
ID=47193270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210328978.1A Active CN102793801B (en) | 2012-09-07 | 2012-09-07 | Tibetan medicine for treating angina pectoris |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102793801B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1364534A (en) * | 2001-01-11 | 2002-08-21 | 杨孟君 | Nano eight ingredient ingredient and eagled wood medicine for clearing away pericardium heat and its preparing method |
| CN101554466A (en) * | 2009-05-19 | 2009-10-14 | 赤峰天奇制药有限责任公司 | Drug for treating coronary heart disease |
-
2012
- 2012-09-07 CN CN201210328978.1A patent/CN102793801B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1364534A (en) * | 2001-01-11 | 2002-08-21 | 杨孟君 | Nano eight ingredient ingredient and eagled wood medicine for clearing away pericardium heat and its preparing method |
| CN101554466A (en) * | 2009-05-19 | 2009-10-14 | 赤峰天奇制药有限责任公司 | Drug for treating coronary heart disease |
Non-Patent Citations (2)
| Title |
|---|
| 卡先加: "藏药治疗风湿性心脏病50例", 《中国民族医药杂志》 * |
| 罗布: "藏药三十五味沉香丸治疗风湿性心脏病100例观察", 《青海医药杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102793801B (en) | 2014-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103721094B (en) | Health tea for blood pressure lowering | |
| CN100544763C (en) | A kind of Chinese medicine for the treatment of coronary heart disease | |
| CN108295177A (en) | It is a kind of to be used to treat Chinese medicine composition of coronary disease and angina pectoris and preparation method thereof | |
| CN107334870A (en) | A kind of composition of hypotensive and preparation method thereof | |
| CN102784240B (en) | Method for preparing traditional Tibetan medicine for treating coronary disease and stenocardia | |
| CN104906399B (en) | One kind treats cardiopathic medicine pill and preparation method thereof | |
| CN102793801B (en) | Tibetan medicine for treating angina pectoris | |
| CN103341069B (en) | Tibetan medicament for treating angina pectoris and preparation method thereof | |
| CN107596244A (en) | One kind treats cardiopathic Chinese medicine and preparation method thereof | |
| CN107441401A (en) | Chinese medicine composition for three high drop and preparation method thereof | |
| CN102698185B (en) | Traditional Tibetan medicine for treating hyperlipidemia and preparation method thereof | |
| CN102526631A (en) | Traditional Chinese medicine preparation, tablet and capsule for curing dilated cardiomyopathy and preparation method | |
| CN102614461B (en) | Spray for rapidly relieving stenocardia and preparation method thereof | |
| CN101632783B (en) | Application of Chinese medicinal composition in preparing medicament for treating cor pulmonale | |
| CN109395045A (en) | A kind of clearing away heat and eliminating dampeness tune sugar-pill and preparation method thereof for treating diabetes B MIDDLE ENERGIZER DAMPNESS-HEAT | |
| CN104758572A (en) | Medicine for treating phlegm retention obstructing lung type cardiac insufficiency and preparation method thereof | |
| CN104383422A (en) | Chinese patent medicine for treating chronic gastritis and preparation method thereof | |
| CN103948767A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, as well as preparation method and application thereof | |
| CN116440224B (en) | Traditional Chinese medicine composition, preparation and preparation method | |
| CN102614459B (en) | Traditional Chinese medicine spray for rapidly curing myocardial ischemia and preparation method thereof | |
| CN106728828A (en) | A kind of Chinese medicine preparation and its preparation technology for treating coronary heart disease | |
| CN106421573A (en) | Drug for treating cough and preparation method thereof | |
| CN105770520A (en) | Medicine preparation used for treating coronary heart disease and application thereof | |
| CN105288095A (en) | Traditional Chinese medicinal composition for treating diabetes, and preparation method thereof | |
| CN105125886A (en) | Traditional Chinese medicine composition for preventing and treating diabetes and complications of diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Tibetan medicament for treating angina pectoris and preparation method thereof Effective date of registration: 20161213 Granted publication date: 20140226 Pledgee: JPMorgan Chase Bank Limited Pledgor: Jiumei Pengcuo Registration number: 2016630000007 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PM01 | Change of the registration of the contract for pledge of patent right | ||
| PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20180620 Registration number: 2016630000007 Pledgee after: Datong silver rich village bank limited liability company Pledgee before: JPMorgan Chase Bank Limited |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20180625 Granted publication date: 20140226 Pledgee: Datong silver rich village bank limited liability company Pledgor: Jiumei Pengcuo Registration number: 2016630000007 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Tibetan medicament for treating angina pectoris and preparation method thereof Effective date of registration: 20180704 Granted publication date: 20140226 Pledgee: Datong silver rich village bank limited liability company Pledgor: Qinghai Jiumei Zang Drug Drug Co.Ltd.|Qinghai Tibetan Hospital Co., Ltd.|Jiumei Pengcuo Registration number: 2018630000005 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210108 Granted publication date: 20140226 Pledgee: Datong silver rich village bank LLC Pledgor: Jiumei Pengcuo Registration number: 2018630000005 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Tibetan medicine for angina pectoris of coronary heart disease Effective date of registration: 20210125 Granted publication date: 20140226 Pledgee: Datong silver rich village bank LLC Pledgor: Jiumei Pengcuo Registration number: Y2021630000001 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |